the issuance of new shares is necessary. Long-term holders could see more than 10 times their money from here. Remember that OPXA has 50 patents for their T-cell Immunotherapy platform. And more important is the fact that Tcelna (imilecleucel-T) has received Fast Track Designation from the United States Food and Drug Administration as a potential treatment for SPMS.
"Clinical trials conducted to date demonstrate that Tcelna® may result in a reduction in the Annualized Relapse Rate (ARR) for patients with MS, slowing of disease progression and evidence of an improvement in disability in a number of MS patients, which could suggest a neuroprotective benefit."